Reading KYNB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KYNB free→Reading KYNB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KYNB free→QuarterlyIQ Insights · KYNB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 11, 2026, Kyntra Bio, Inc. (“Kyntra Bio”) issued a press release announcing financial results for the quarter ended March 31, 2026. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the lia…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 2, 2026, Kyntra Bio, Inc. (“Kyntra Bio” or the “Company”) received a letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market notifying us that the Company no longer complies with the Nasdaq Global Select Market continued listing requirement of $50 million in total assets and total revenue for the most recently completed fiscal year (or two of the last three most…
Results of Operations and Financial Condition. On March 16, 2026, Kyntra Bio, Inc. (“Kyntra Bio”) issued a press release announcing financial results for the quarter and year ended December 31, 2025. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subj…
Results of Operations and Financial Condition. On November 10, 2025, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter ended September 30, 2025. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to th…
Completion of Acquisition or Disposition of Assets. This Current Report on Form 8-K is being filed in connection with the completion on August 29, 2025, or the closing (the “Closing”), of the transaction contemplated by the Share Purchase Agreement, dated February 20, 2025, and entered into with AstraZeneca Treasury Limited (“AstraZeneca”) pursuant to which we and our indirect subsidiary FibroGen China Anemia Holdings, Ltd. sold all of the issued and outstanding equity interests of FibroGen I…
Other Events. On August 29, 2025, FibroGen, Inc. (the “Company”) completed the sale of FibroGen International (Hong Kong) Ltd., (including its subsidiaries, “FibroGen China”) to AstraZeneca Treasury Limited (“AstraZeneca”), for a total consideration of approximately $220 million comprised of $85 million in enterprise value and approximately $135 million in net cash held in China. The sale to AstraZeneca is made pursuant to the Share Purchase Agreement between the parties, dated February 20, 2…
Other Events. On August 18, 2025, FibroGen, Inc. (the “Company”) issued a press release in which the Company announced that it received China regulatory approval for the sale of FibroGen International (Hong Kong) Ltd., (including its subsidiaries, “FibroGen China”) to AstraZeneca Treasury Limited (“AstraZeneca”), pursuant to the Share Purchase Agreement, dated February 20, 2025. After review, the China State Administration for Market Regulation decided not to prohibit the proposed acquisition…
Entry into a Material Definitive Agreement. On August 12, 2025, FibroGen entered into the fourth amendment (“Fourth Amendment”) to the financing agreement, dated as of April 29, 2023 as amended (“Financing Agreement”) with investment funds managed by Morgan Stanley Tactical Value, as lenders (the “Lenders”) and Wilmington Trust National Association, as administrative agent for the Lenders (the “Administrative Agent”), as previously amended. The Fourth Amendment further reduces the minimum qua…
Results of Operations and Financial Condition. On August 11, 2025, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabi…
Entry into a Material Definitive Agreement. On July 14, 2025, FibroGen entered into the third amendment (“Third Amendment”) to the financing agreement, dated as of April 29, 2023 as amended (“Financing Agreement”) with investment funds managed by Morgan Stanley Tactical Value, as lenders (the “Lenders”) and Wilmington Trust National Association, as administrative agent for the Lenders (the “Administrative Agent”), as previously amended. The Third Amendment further reduces the minimum qualifie…
Termination of a Material Definitive Agreement On June 12, 2025, FibroGen (“FibroGen” or the “Company”) entered into a Termination, Asset Transfer and License Agreement (the “Agreement”) with HiFiBiO Inc. (“HiFiBiO”). The Agreement terminates the Exclusive License and Option Agreement between the parties, dated June 16, 2021, as amended on February 14, 2024 (the “License Agreement”), and all rights and obligations of FibroGen under the License Agreement shall cease and terminate, subject to c…
Material Modification to Rights of Security Holders. To the extent required by
Entry into a Material Definitive Agreement. On June 5, 2025, FibroGen entered into the second amendment (“Second Amendment”) to the financing agreement, dated as of April 29, 2023 as amended (“Financing Agreement”) with investment funds managed by Morgan Stanley Tactical Value, as lenders (the “Lenders”) and Wilmington Trust National Association, as administrative agent for the Lenders (the “Administrative Agent”). The Second Amendment further reduces the minimum qualified cash balance requir…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Appointment Effective June 4, 2025, the Board of the Company, upon recommendation of the Nominating and Corporate Governance Committee, appointed Michael Kauffman, M.D., Ph.D. as a Class III director of the Company. Dr. Kauffman was appointed to the Audit Committee and Compensation Committee of the Board. FibroGen is delighted to welcome D…
Results of Operations and Financial Condition. On May 12, 2025, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter ended March 31, 2025. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabili…
Entry into a Material Definitive Agreement On March 28, 2025, FibroGen, Inc. and Fortis Therapeutics, Inc. (collectively, the “Parties”) entered into Amendment No.1 to the First Amended and Restated Evaluation Agreement, dated June 6, 2024, which amended and restated the original agreement dated May 5, 2023. On March 28, 2025, the Parties entered into Amendment No.1 to the First Amended and Restated Option Agreement and Plan of Merger, dated June 6, 2024, which amended and restated the origin…
Results of Operations and Financial Condition. On March 17, 2025, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter and year ended December 31, 2024. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on September 12, 2024, FibroGen received a letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market notifying FibroGen that for 30 consecutive business days the bid price of FibroGen’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1) (the “…
Entry into a Material Definitive Agreement. On February 24, 2025, FibroGen, Inc. (the “Company”) entered into an ATM Equity Offering Sales Agreement (the “Sales Agreement”) with BofA Securities, Inc. (“BofA”), under which it may offer and sell its common stock having aggregate sales proceeds of up to $30.0 million from time to time through BofA as its sales agent. Sales of the Company’s common stock through BofA, if any, will be made by any method permitted by law deemed to be an “at the mark…
Entry into a Material Definitive Agreement On February 19, 2025, FibroGen, Inc. (the “Company”, “we”, “us”, “our”, or “FibroGen”) entered into a share purchase agreement (the “Share Purchase Agreement”) with AstraZeneca Treasury Limited (“AstraZeneca”) pursuant to which we and our indirect subsidiary FibroGen China Anemia Holdings, Ltd. agreed to sell all of the issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. (“FibroGen International”) to AstraZeneca for an…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Upon the closing of the sale of FibroGen International pursuant to the Share Purchase Agreement, Christine L. Chung, who currently serves as our Senior Vice President, China Operations, will cease employment with us. Ms. Chung is entitled to certain severance benefits pursuant to our executive officer change in control and severance agreement, whic…
Results of Operations and Financial Condition. On February 20, 2025, we announced that as of December 31, 2024, we estimated that we had approximately $121.1 million in cash, cash equivalents, and accounts receivable. This preliminary financial information is unaudited and is based on currently available information and does not present all necessary information for an understanding of our financial condition as of December 31, 2024 or our results of operations for the year ended December 31,…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.